20
SEP
2017

NW BIO Announces Registered Direct Offering Of $1.75 Million

Posted By :
Comments : Off
BETHESDA, Md., September 20, 2017 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with institutional investors for a registered direct offering with gross proceeds of $1.75 million. In the transaction, the Company will sell approximately 8.75 million shares of common stock...
Read More
01
SEP
2017

DCVax® Clinical Program Updates Presented By Dr. Marnix Bosch At Boston Scientific Conference

Posted By :
Comments : Off
DCVax®-L Phase III GBM Trial & DCVax-Direct Phase I/II Updates;  Overview Of A Broader Range Of DC Vax Public Data     BETHESDA, Md., September 1, 2017 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix L. Bosch, MBA, PhD and Chief Technical Officer of NW Bio presented an update on the Phase III Trial o...
Read More
22
JUN
2017

NWBio Closes 3-Year Convertible Debt Exchange and Financing, and Completes Payoff of Last $5 Million of 2014 Bonds

Posted By :
Comments : Off
Debt Convertible at $0.25, $.50 and $1.00;  Secured By UK Property   BETHESDA, MD, June 22, 2017 – Northwest Biotherapeutics, Inc. (OTCQB: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced today that it has closed a convertible debt exchange and financing transaction with a non-affiliated investor and has completed the payoff of the...
Read More
05
JUN
2017

Dr. Marnix Bosch To Present Updates About DCVax® Clinical Programs Today

Posted By :
Comments : Off
Updates to Include Both DCVax®-L Phase III Trial and DCVax®-Direct Phase I/II Trial BETHESDA, Md., June 5, 2017 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that this afternoon at 3:00 p.m. Central Time in the Industry Expert Theater in the Exhibit Hall at the ASCO Conference in the McCormick Place Convention Center in...
Read More
23
MAR
2017

NW Bio Has Closed On Its Registered Direct Offering Of $7.5 Million With Institutional Investors

Posted By :
Comments : Off
BETHESDA, Md., March 23, 2017 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that yesterday it closed on the $7.5 million financing it announced last Friday, March 17, 2017. The Company sold to several institutional investors securities totaling 28,843,692 shares, comprised of 18,843,692 common shares at $.26 per share,...
Read More